Helicobacter pylori infection
Conditions
Interventions
Quadruple Therapy:PPI+bismuth+two antibiotics,2w
High dose fucoidan polysaccharide:Fucoidan polysaccharide,2g/d,6w
Quadruple Therapy+ Low dose fucoidan polysaccharide:PPI+bismuth+two antibiotics,2w+Fucoidan polysaccharide,1g/d,6w
Quadruple Therapy+Low dose fucoidan polysaccharide+Probiotics:PPI+bismuth+two antibiotics,2w+Fucoidan polysaccharide,1g/d,6w+Probiotics,2g/d,6w
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: ? Age:18-65 years old; ?Patients with untreated Hp infection indicated by the C13 breath test.DOB=4; ?No history of smoking and alcoholism, and usual living and eating during treatment; ?Volunteer to participate in the study, sign the informed consent, compliance is good, can be followed up; ?No drugs have been taken within 1 month before the first specimen collection: antibiotics (oral, intramuscular and intravenous infusion), microecological preparations (probiotics, prebiotics and synbiotics, etc.), various drugs that inhibit gastric acid secretion, cytokines, immunosuppressants and cytotoxic preparations, hormone drugs and other drugs that affect the gastrointestinal flora; ?Don't use UNSAIDs. ?No other acid-suppressive medications, antibiotics and other drugs that affect the the gastrointestinal micobiota during the treatment; ? No history of Hp infection.
Exclusion criteria
Exclusion criteria: ?Patients who do not meet the inclusion criteria. ?Patients with a history of previous gastric surgery. ?Pregnant women and nursing mothers. ?Patients with major systemic diseases(e.g:Adrenal insufficiency,Inflammatory bowel disease,Rheumatoid arthritis,Systemic vasculitis,AIDS etc). ?Use of antibiotics, anti-gastric acid-secreting drugs, bismuth, probiotics within 8 weeks or allergy to any of the above drugs. ?Patients who refuse to receive Hp eradication treatment or are unable to take medication as required. ?Patients who take other drugs that affect the intestinal flora. ?Subjects who are participating in clinical studies of other drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| C13 Breath Test after the therapy;Intestinal flora before the therapy;Intestinal flora after the therapy; | — |
Countries
China
Contacts
Public ContactMai Shi
China-Japan Friendship Hospital
Outcome results
None listed